Loading…
Abbott plans to close its acquisition of Alere on October 3, 2017, after receiving anti-trust approvals. The deal is valued at $5.3 billion, down from the initial $5.8 billion. Abbott will divest certain assets to Siemens and Quidel.
Siemens Healthineers signed a definitive agreement to purchase Alere's blood diagnostic systems unit Epocal, including the epoc Blood Analysis System. Financial details were not disclosed.
Abbott and Alere announced amended terms for Abbott's pending acquisition of Alere. Abbott will pay $51 per share for an expected equity value of $5.3 billion, down from $5.8 billion. The companies have dismissed lawsuits against each other and extended the regulatory approval deadline to September 30, 2017.